Raloxifene

The active agent raloxifene is used for the treatment and prevention of osteoporosis in postmenopausal women. Daiichi Sankyo Europe bought the marketing and distribution rights for the use of raloxifene in osteoporosis from Eli Lilly.

Healthcare professionals can read more about the treatment and prevention of osteoporosis at: www.evista.eu

Patients can obtain more extensive information about osteoporosis, the risk factors for the disease and its prevention, including an individual risk calculator, at: www.osteoporosis-disease.eu